Navigating Haploidentical Stem Cell Transplantation in Congenital Amegakaryocytic Thrombocytopenia With Prior Intracranial Bleeding: Report of Two Pediatric Cases

Read full text Summarise with VIRAT
Authors: Aditi Tulsiyan, Nita Radhakrishnan, Anuj Singh, Sudipto Bhattacharya, Hari Gaire, Satyam Arora, Seema Dua, Savitri Singh, Anukriti Srivastava
Cited by: 0
References: 20

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Congenital amegakaryocytic thrombocytopenia (CAMT) is a rare inherited bone marrow failure syndrome caused by biallelic myeloproliferative leukemia (MPL) variants, for which hematopoietic stem cell transplantation (HSCT) is the only curative therapy. We report two children with genetically confirmed CAMT and prior intracranial hemorrhage who underwent haploidentical peripheral blood HSCT with reduced intensity conditioning and post-transplant cyclophosphamide. Individualized management included immunomodulation (bortezomib for alloimmune platelet refractoriness in one child; rituximab for B-cell depletion in the other) and an intensified platelet transfusion strategy to maintain hemostatic stability during the peri-transplant period. Both achieved prompt engraftment, transfusion independence, and sustained donor chimerism without neurological deterioration. These cases demonstrate the feasibility of haploidentical HSCT in high-risk CAMT.

Fields of Study & Subjects

Platelet Disorders and Treatments Hematopoietic Stem Cell Transplantation Immunodeficiency and Autoimmune Disorders

Publication details

Journal / source
Cureus
Volume
18
Issue
3
Pages
e106037–e106037
Publication date
28 March 2026
Language
EN